CN103126996A - 用于鼻内递送的方法和组合物 - Google Patents

用于鼻内递送的方法和组合物 Download PDF

Info

Publication number
CN103126996A
CN103126996A CN2013100510480A CN201310051048A CN103126996A CN 103126996 A CN103126996 A CN 103126996A CN 2013100510480 A CN2013100510480 A CN 2013100510480A CN 201310051048 A CN201310051048 A CN 201310051048A CN 103126996 A CN103126996 A CN 103126996A
Authority
CN
China
Prior art keywords
virus
microns
antigen
vaccine
powder formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100510480A
Other languages
English (en)
Chinese (zh)
Inventor
永田良一
治田俊二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Research Ltd
Original Assignee
Common financial group legal person chemical and serum therapy research institute
Translational Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Common financial group legal person chemical and serum therapy research institute, Translational Research Ltd filed Critical Common financial group legal person chemical and serum therapy research institute
Publication of CN103126996A publication Critical patent/CN103126996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M3/00—Automatic or semi-automatic exchanges
    • H04M3/42—Systems providing special services or facilities to subscribers
    • H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/10—Connection setup
    • H04W76/15—Setup of multiple wireless link connections
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marketing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN2013100510480A 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物 Pending CN103126996A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
US61/324,542 2010-04-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180027287.1A Division CN102933230B (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Publications (1)

Publication Number Publication Date
CN103126996A true CN103126996A (zh) 2013-06-05

Family

ID=44798502

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2013100510480A Pending CN103126996A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN201710415508.1A Pending CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN201180027287.1A Active CN102933230B (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710415508.1A Pending CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN201180027287.1A Active CN102933230B (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Country Status (12)

Country Link
US (2) US9687536B2 (https=)
EP (2) EP2689785B1 (https=)
JP (5) JP5771626B2 (https=)
KR (3) KR20130083376A (https=)
CN (3) CN103126996A (https=)
BR (1) BR112012026116A2 (https=)
CA (2) CA2796593C (https=)
CU (1) CU20120148A7 (https=)
ES (1) ES2874817T3 (https=)
RU (1) RU2012144612A (https=)
SG (1) SG184304A1 (https=)
WO (1) WO2011129120A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113583970A (zh) * 2021-07-29 2021-11-02 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126996A (zh) 2010-04-15 2013-06-05 株式会社新日本科学 用于鼻内递送的方法和组合物
BR112014014594B1 (pt) 2011-12-16 2021-02-17 Indosys Limited dispositivo de liberação de medicamento seco em pó
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (zh) * 2013-05-30 2017-06-06 上海医药工业研究院 一种鼻用疫苗组合物粉体制剂及其制备方法
EP3041504B1 (en) 2013-09-03 2021-08-25 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
WO2017047089A1 (en) * 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
US20190275136A1 (en) * 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
WO2019118393A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
AU2019336940B2 (en) * 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
BR112021016059A2 (pt) * 2019-02-15 2021-10-13 Serum Institute Of India Pvt Ltd. Composição de vacina de vírus de influenza atenuada viva e processo para a preparação da mesma
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
WO2021194038A1 (ko) * 2020-03-24 2021-09-30 안병철 어린 포유동물의 점막관련 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도
CN119866231A (zh) 2022-09-01 2025-04-22 锡拉坎岛有限公司 干粉药物递送装置
JP2025540325A (ja) * 2022-12-07 2025-12-11 ズー，ダオチョン 融合タンパク質の製剤および使用
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
AU2024282997A1 (en) * 2023-05-31 2026-01-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472605A (zh) * 2006-06-09 2009-07-01 布鲁诺·西尔韦斯特里尼 用于舌下给药疫苗的药物组合物，制备该药物组合物的方法以及其应用
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009819A1 (en) * 1992-11-03 1994-05-11 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (zh) * 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 一种鼻用鲑降钙素粉末吸入剂及制备方法
AU2002346424A1 (en) 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1701738B1 (en) * 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
US20060292173A1 (en) * 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
EP1954308B1 (en) 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
BRPI0616879A2 (pt) * 2005-10-04 2011-07-05 Alk Abello As formulação de vacina sólida
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US20080226729A1 (en) 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2066354B1 (en) * 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
CN101959527B (zh) * 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
US20110150926A1 (en) 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
AU2012244077B2 (en) 2010-04-15 2015-06-18 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
CN103126996A (zh) * 2010-04-15 2013-06-05 株式会社新日本科学 用于鼻内递送的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472605A (zh) * 2006-06-09 2009-07-01 布鲁诺·西尔韦斯特里尼 用于舌下给药疫苗的药物组合物，制备该药物组合物的方法以及其应用
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT J.GARMISE ET.AL: "Dry Powder Nasal Vaccines as an Alternative to Needle-Based Delivery", 《CRITICAL REVIEWS TM IN THERAPEUTIC DRUG CARRIER SYSTEMS》, vol. 26, no. 1, 31 December 2009 (2009-12-31), pages 1 - 27, XP009135117 *
SULING ZHAI ET AL.: "Effect of Freezing Rates and Excipients on the Infectivity of a Live Viral Vaccine during Lyophilization", 《BIOTECHNOL.PROG.》, vol. 20, no. 4, 31 December 2004 (2004-12-31), pages 1113 - 1120 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113583970A (zh) * 2021-07-29 2021-11-02 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN113583970B (zh) * 2021-07-29 2023-05-12 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Also Published As

Publication number Publication date
US20130129781A1 (en) 2013-05-23
CN102933230A (zh) 2013-02-13
JP2016006119A (ja) 2016-01-14
CA2796593C (en) 2020-12-15
JP6827488B2 (ja) 2021-02-10
CA2993242A1 (en) 2011-10-20
US10463723B2 (en) 2019-11-05
CN102933230B (zh) 2016-03-02
JP2013126989A (ja) 2013-06-27
RU2012144612A (ru) 2014-05-20
KR101960102B1 (ko) 2019-03-19
CA2993242C (en) 2020-12-15
BR112012026116A2 (pt) 2016-06-28
KR20130064741A (ko) 2013-06-18
EP2689785A1 (en) 2014-01-29
CA2796593A1 (en) 2011-10-20
CN107260689A (zh) 2017-10-20
US9687536B2 (en) 2017-06-27
ES2874817T3 (es) 2021-11-05
JP2017186377A (ja) 2017-10-12
JP2013523602A (ja) 2013-06-17
KR102136036B1 (ko) 2020-07-20
JP2019104751A (ja) 2019-06-27
JP5771626B2 (ja) 2015-09-02
CU20120148A7 (es) 2013-01-30
EP2558120A1 (en) 2013-02-20
EP2558120A4 (en) 2013-08-28
WO2011129120A1 (en) 2011-10-20
KR20190028555A (ko) 2019-03-18
SG184304A1 (en) 2012-11-29
KR20130083376A (ko) 2013-07-22
US20130273120A1 (en) 2013-10-17
EP2689785B1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
CN102933230B (zh) 用于鼻内递送的方法和组合物
JP7082703B2 (ja) ワクチン組成物
Dumpa et al. Stability of vaccines
JP2011514337A (ja) 糖ガラス化ウィルス様粒子（ｖｌｐ）
CN106456585B (zh) 疫苗组合物
Perrie et al. Recent developments in particulate-based vaccines
Wu et al. Nanovaccines to combat virus‐related diseases
AU2012244077B2 (en) Methods and compositions for intranasal delivery
EP4651855A1 (en) Compositions, methods, and uses for polynucleotide formulations for drying and prolonged storage
Zhu et al. Promising Adjuvants and Platforms for Influenza Vaccine Development. Pharmaceutics 2021, 13, 68
Hendy Improved Delivery of a Broadly Active Influenza Subunit Vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

Effective date: 20130523

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130523

Address after: Kagoshima County, Japan

Applicant after: Translational Res Ltd.

Address before: Kagoshima County, Japan

Applicant before: Translational Res Ltd.

Applicant before: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130605

RJ01 Rejection of invention patent application after publication